MedWatch

Genmab has a worthy successor to Darzalex, bank says

Swedish Handelsbanken has seen data for Hexabody-CD38 that indicates it is ten times more potent than Darzalex – but there are hurdles ahead for the Danish biotech company.

Photo: Tuala Hjarnø / Genmab / PR

Genmab might have a worthy successor to bestseller Darzalex on its hands, assesses Swedish bank Handelsbanken. However, there are also risks linked to bringing out new cancer drugs, as the US might soon tighten development requirements for such medicines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs